Adjuvant osimertinib in patients with completely resected, stage IB-IIIB NSCLC with uncommon EGFR mutations (ADMIN): Clinical characteristics, genomic profile and molecular residual disease

被引：0
|
作者：
Liu, C. [1 ]
Han, Y. [2 ]
Leng, X. [2 ]
Yue, D. [3 ]
Zhao, G. [4 ]
Cheng, C. [5 ]
Li, G. [6 ]
Liang, N. [7 ]
Zhao, J. [8 ]
Liu, S. [9 ]
Huang, W. [10 ]
Wang, J. [10 ]
Liu, L. [11 ,12 ]
机构：
[1] Sichuan Univ, West China Hosp, West China Sch Med, Dept Thorac Surg, Chengdu, Peoples R China
[2] UESTC, Dept Thorac Surg, Sichuan Canc Hosp & Inst, Affiliated Canc Hosp,Sch Med, Chengdu, Peoples R China
[3] TMUCIH Tianjin Med Univ Canc Inst & Hosp, Lung Canc Dept, Tianjin, Peoples R China
[4] Ningbo 2 Hosp, Dept Thorac Surg, Ningbo, Peoples R China
[5] Sun Yat Sen Univ, Dept Thorac Surg, First Affiliated Hosp 1, Guangzhou, Peoples R China
[6] Yunnan Canc Hosp, Dept Thorac Surg, Kunming, Yunnan, Peoples R China
[7] Beijing Xiehe Hosp, PUMCH Peking Union Med Coll Hosp, Dept Thorac Surg, Dongdan Campus, Beijing, Peoples R China
[8] Soochow Univ, Affiliated Hosp 1, Dept Thorac Surg, Suzhou, Peoples R China
[9] Fujian Prov Canc Hosp, Dept Thorac Surg, Fuzhou, Peoples R China
[10] AstraZeneca, Dept Med Affairs, Shanghai, Peoples R China
[11] Sichuan Univ, Dept Thorac Surg, West China Hosp, Chengdu, Peoples R China
[12] Sichuan Univ, Inst Thorac Oncol, West China Hosp, Chengdu, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.624
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
597P
引用
收藏
页码：S1617 / S1617
页数：1
相关论文
共 17 条
  • [1] Adjuvant osimertinib in patients with completely resected, stage IB-IIIB non-small cell lung cancer with uncommon EGFR mutations: A phase II, open-label, single arm, multicenter, exploratory study
    Liu, C.
    Mei, J.
    Lin, F.
    Lin, Y.
    Chen, Y.
    Liu, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S113 - S114
  • [2] Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations
    Geng, R.
    Chen, Y.
    Miao, J.
    Liu, H.
    Qin, Y.
    Han, Z.
    Li, S.
    Guan, Y.
    Wu, H.
    Zhao, Y.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S120 - S121
  • [3] TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC
    Soo, R.
    De Marinis, F.
    Han, J. -Y.
    Ho, C. M. J.
    Lin, Y.
    Servidio, L.
    Sandelin, M.
    Popat, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S272 - S272
  • [4] Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer
    Herbst, Roy S.
    John, Thomas
    Grohe, Christian
    Goldman, Jonathan W.
    Kato, Terufumi
    Laktionov, Konstantin
    Bonanno, Laura
    Tiseo, Marcello
    Majem, Margarita
    Domine, Manuel
    Ahn, Myung-Ju
    Kowalski, Dariusz M.
    Perol, Maurice
    Sriuranpong, Virote
    Ozguroglu, Mustafa
    Bhetariya, Preetida
    Markovets, Aleksandra
    Rukazenkov, Yuri
    Muldoon, Caitlin
    Robichaux, Jacqulyne
    Hartmaier, Ryan
    Tsuboi, Masahiro
    Wu, Yi-Long
    NATURE MEDICINE, 2025,
  • [5] Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC)
    John, Tom
    Grohe, Christian
    Goldman, Jonathan W.
    Kato, Terufumi
    Laktionov, Konstantin K.
    Bonanno, Laura
    Tiseo, Marcello
    Majem, Margarita
    Domine, Manuel, Sr.
    Ahn, Myung-Ju
    Perol, Maurice
    Hartmaier, Ryan
    Robichaux, Jacqulyne
    Bhetariya, Preetida
    Markovets, Aleksandra
    Rukazenkov, Yuri
    Muldoon, Caitlin
    Herbst, Roy S.
    Tsuboi, Masahiro
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] Adjuvant Aumolertinib in Patients with Completely Resected, Stage IA2-IIIA Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations
    Zhang, Q.
    Ke, L.
    Huang, S.
    Yang, Y.
    He, T.
    Sun, H.
    Wu, Z.
    Zhang, X.
    Lv, W.
    Hu, J.
    Ye, J.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S555 - S556
  • [7] TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection
    Soo, Ross Andrew
    de Marinis, Filippo
    Han, Ji-Youn
    Ho, James Chung-Man
    Martin, Emma
    Servidio, Leslie
    Sandelin, Martin
    Popat, Sanjay
    CLINICAL LUNG CANCER, 2024, 25 (01) : 80 - 84
  • [8] Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial
    Ou, Wei
    Li, Ning
    Wang, Bao-Xiao
    Zhu, Teng-Fei
    Shen, Zhi-Lin
    Wang, Tao
    Chang, Wu-Guang
    Chang, Zeng-Hao
    Hu, Xin-Xin
    Pu, Yue
    Ding, Lie -Ming
    Wang, Si-Yu
    ECLINICALMEDICINE, 2023, 57
  • [9] Long-term tolerability of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC) from ADAURA
    John, T.
    Grohe, C.
    Goldman, J.
    De Marinis, F.
    Kato, T.
    Wang, Q.
    Choi, J-H.
    Melotti, B.
    Fidler, M.
    Sainsbury, L.
    Stachowiak, M.
    Taggart, S.
    Wu, Y-L.
    Tsuboi, M.
    Herbst, R. S.
    Tarruella, M. Majem
    ANNALS OF ONCOLOGY, 2022, 33 : S1548 - S1548
  • [10] Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
    Tsuboi, M.
    Wu, Y-L.
    Grohe, C.
    John, T.
    Majem Tarruella, M.
    Wang, J.
    Kato, T.
    Goldman, J. W.
    Kim, S-W.
    Yu, C-J.
    Vu, H. Vinh
    Mukhametshina, G.
    Akewanlop, C.
    de Marinis, F.
    Shepherd, F. A.
    Urban, D.
    Stachowiak, M.
    Bolanos, A. L.
    Huang, X.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1413 - S1414
12